Get the Stockscreener App
9.755
1.51%
0.145
Kura Oncology Inc stock is traded at $9.755, with a volume of 1.05M.
It is up +1.51% in the last 24 hours and down -13.67% over the past month.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$9.61
Open:
$9.825
24h Volume:
1.05M
Relative Volume:
0.62
Market Cap:
$867.81M
Revenue:
$71.64M
Net Income/Loss:
$-294.57M
P/E Ratio:
-2.9137
EPS:
-3.348
Net Cash Flow:
$-84.46M
1W Performance:
-7.27%
1M Performance:
-13.67%
6M Performance:
+7.79%
1Y Performance:
-5.20%
1-Day Range:
$9.60
$9.90
1-Week Range:
$9.57
$10.68
52-Week Range:
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.755 | 867.81M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
508.15 | 128.80B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.82 | 95.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.63 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.39 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.90 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-26 | Initiated | JP Morgan | Overweight |
| Apr-14-26 | Initiated | Lake Street | Buy |
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes - GlobeNewswire
Caspian Therapeutics and Kura Oncology to host investor call By Investing.com - Investing.com
Caspian Therapeutics and Kura Oncology to Host Investor Webcast on Caspian Formation and KO-7246 Data from EASD Meeting - Quiver Quantitative
Caspian Therapeutics and Kura Oncology to Host Investor - GlobeNewswire
Kura Oncology (KURA) Stock Price, News & Analysis - Stock Titan
Kura Oncology Share PriceKURA, RNS News, Articles, Quotes, & Charts (NASDAQ:KURA) - Proactive financial news
Why Is KURA Stock Rallying 8% After-Hours? - Stocktwits
Kura Oncology Inc. Company & People | KUR - Barron's
Nine new hires get rights to buy 128,250 Kura shares, phased in over four years. - Stock Titan
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kura Oncology, Inc. : JP Morgan Initiates Cov - Moomoo
Kura Oncology, Inc. (KURA) stock price, news, quote and history - uk.finance.yahoo.com
Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kura Oncology CCO Brian Powl sells over $345k in company stock - Investing.com
Kura Oncology SVP sells $48,360 of stock - Investing.com
Kura Oncology COO Kathleen Ford sells $111,930 in company stock - Investing.com
A tax-related sale followed stock vesting: Kura Oncology (KURA) executive sold 4,607 shares. - Stock Titan
One sale covered taxes; two followed a trading plan. Kura Oncology (KURA) executive sold 32,450 shares. - Stock Titan
Return on equity % of Kura Oncology, Inc. – HAN:KUR - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
Kura Oncology, Inc. Revenue Breakdown – HAN:KUR - TradingView
ETFs Investing in Kura Oncology, Inc. Stocks - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
After three earlier sales, a Kura Oncology (KURA) officer proposes another share sale - Stock Titan
After selling 12,448 shares, a Kura Oncology (KURA) officer proposes selling 28,802 more. - Stock Titan
Shares valued at $74,308.56 are proposed for sale by Kura Oncology (KURA) officer Kathleen Ford. - Stock Titan
An August sale of 31,487 stock units precedes another proposed sale by Kura Oncology (KURA) officer Teresa Bair. - Stock Titan
A planned $133,940 share sale at Kura Oncology (KURA) involves officer Mollie Leoni. - Stock Titan
Shares valued at $49,571 are in a proposed sale by Kura Oncology (KURA) officer Thomas James Doyle. - Stock Titan
Two sales, two reasons: Kura Oncology (KURA) medical chief sold shares to cover taxes and under a trading plan. - Stock Titan
A stock award triggers a tax-covering share sale by Kura Oncology (KURA) COO Kathleen Ford. - Stock Titan
A tax-related sale leaves Kura Oncology (KURA) legal chief with 187,002 shares. - Stock Titan
Form 144 KURA ONCOLOGY For: 25 September By Investing.com - Investing.com Canada
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514. - Stock Titan
Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech Innovator with a 173% Potential Upside - DirectorsTalk Interviews
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Oncology Maintains 49.2% Stake in Caspian Therapeutics Following $50M Series A Funding - Kalkine Media
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - AOL.com
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions - Investing.com India
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - Yahoo Finance
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Appoints Jennifer Fulk as New CFO - The Globe and Mail
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kura Oncology Inc Stock (KURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KATHLEEN FORD | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
3,668 |
38,917 |
0 |
| MOLLIE LEONI | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
28,802 |
305,589 |
0 |
| BRIAN POWL | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
15,430 |
163,712 |
0 |
| Powl Brian T. | Chief Commercial Officer |
Sep 29 '26 |
Sale |
10.75 |
15,430 |
165,852 |
136,819 |
| Leoni Mollie | Chief Medical Officer |
Sep 29 '26 |
Sale |
10.75 |
28,802 |
309,567 |
141,095 |
| FORD KATHLEEN | Chief Operating Officer |
Sep 29 '26 |
Sale |
10.75 |
3,668 |
39,437 |
142,986 |
| DOYLE THOMAS JAMES | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
4,607 |
49,571 |
0 |
| FORD KATHLEEN | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
6,906 |
74,309 |
0 |
| BAIR TERESA BROPHY | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
8,442 |
90,836 |
0 |
| Powl Brian T. | Chief Commercial Officer |
Sep 28 '26 |
Sale |
10.53 |
17,020 |
179,183 |
152,249 |
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):